HK1202459A1 - Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders - Google Patents

Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Info

Publication number
HK1202459A1
HK1202459A1 HK15103243.2A HK15103243A HK1202459A1 HK 1202459 A1 HK1202459 A1 HK 1202459A1 HK 15103243 A HK15103243 A HK 15103243A HK 1202459 A1 HK1202459 A1 HK 1202459A1
Authority
HK
Hong Kong
Prior art keywords
antagonists
sleep disorders
inverse agonists
ghrelin receptor
treating sleep
Prior art date
Application number
HK15103243.2A
Other languages
English (en)
Chinese (zh)
Inventor
．丹尼
．傑克遜
．索南伯格
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1202459A1 publication Critical patent/HK1202459A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103243.2A 2012-06-04 2015-03-31 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders HK1202459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US201361812416P 2013-04-16 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (1)

Publication Number Publication Date
HK1202459A1 true HK1202459A1 (en) 2015-10-02

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103243.2A HK1202459A1 (en) 2012-06-04 2015-03-31 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Country Status (16)

Country Link
US (1) US9370516B2 (xx)
EP (1) EP2854856B1 (xx)
JP (1) JP6165852B2 (xx)
KR (1) KR101708989B1 (xx)
CN (1) CN104334193A (xx)
AU (1) AU2013273263B2 (xx)
BR (1) BR112014029577A2 (xx)
CA (1) CA2874196C (xx)
ES (1) ES2716303T3 (xx)
HK (1) HK1202459A1 (xx)
IL (1) IL235883A0 (xx)
MX (1) MX2014014813A (xx)
RU (1) RU2600895C2 (xx)
SG (1) SG11201407387UA (xx)
WO (1) WO2013182933A1 (xx)
ZA (1) ZA201408672B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN100563660C (zh) * 2002-12-20 2009-12-02 麦克莱恩医院 用于正常化睡眠/觉醒周期的化合物
US20050171132A1 (en) 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
EP2043634A2 (en) * 2006-07-12 2009-04-08 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
MX2012010772A (es) * 2010-03-19 2012-11-06 Pfizer Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3,5]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina.

Also Published As

Publication number Publication date
CN104334193A (zh) 2015-02-04
US9370516B2 (en) 2016-06-21
CA2874196A1 (en) 2013-12-12
MX2014014813A (es) 2015-02-12
JP2015518876A (ja) 2015-07-06
CA2874196C (en) 2016-12-06
KR20150013236A (ko) 2015-02-04
EP2854856A1 (en) 2015-04-08
WO2013182933A1 (en) 2013-12-12
US20150119381A1 (en) 2015-04-30
ZA201408672B (en) 2016-09-28
EP2854856B1 (en) 2019-01-23
AU2013273263B2 (en) 2017-08-24
KR101708989B1 (ko) 2017-02-21
SG11201407387UA (en) 2014-12-30
IL235883A0 (en) 2015-01-29
RU2014146109A (ru) 2016-07-27
BR112014029577A2 (pt) 2017-06-27
AU2013273263A1 (en) 2014-11-27
JP6165852B2 (ja) 2017-07-19
RU2600895C2 (ru) 2016-10-27
ES2716303T3 (es) 2019-06-11

Similar Documents

Publication Publication Date Title
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
HK1252279A1 (zh) 5- ht3受體拮抗劑
IL225758A0 (en) Preparations containing combinations of serotonin agonists and their uses
HK1220386A1 (zh) 受體拮抗劑在軟骨疾病的治療中的用途
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
HRP20150974T1 (xx) Derivati 2-amino-3-(imidazol-2-il)-piridin-4-ona i njihova uporaba kao inhibitora vegf receptora kinaze
HK1204286A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
EP2934565A4 (en) GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC ILLNESSES
IL234412B (en) The iloperidone metabolite for use in the treatment of psychiatric diseases
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
HK1198580A1 (en) Novel therapeutic use of p75 receptor antagonists p75
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS